Nanoparticles for drug delivery to the anterior segment of the eye

Dileep R. Janagam, Linfeng Wu, Tao Lowe

Research output: Contribution to journalReview article

22 Citations (Scopus)

Abstract

Commercially available ocular drug delivery systems are effective but less efficacious to manage diseases/disorders of the anterior segment of the eye. Recent advances in nanotechnology and molecular biology offer a great opportunity for efficacious ocular drug delivery for the treatments of anterior segment diseases/disorders. Nanoparticles have been designed for preparing eye drops or injectable solutions to surmount ocular obstacles faced after administration. Better drug pharmacokinetics, pharmacodynamics, non-specific toxicity, immunogenicity, and biorecognition can be achieved to improve drug efficacy when drugs are loaded in the nanoparticles. Despite the fact that a number of review articles have been published at various points in the past regarding nanoparticles for drug delivery, there is not a review yet focusing on the development of nanoparticles for ocular drug delivery to the anterior segment of the eye. This review fills in the gap and summarizes the development of nanoparticles as drug carriers for improving the penetration and bioavailability of drugs to the anterior segment of the eye.

Original languageEnglish (US)
Pages (from-to)31-64
Number of pages34
JournalAdvanced Drug Delivery Reviews
Volume122
DOIs
StatePublished - Dec 1 2017

Fingerprint

Anterior Eye Segment
Nanoparticles
Pharmaceutical Preparations
Drug Carriers
Nanotechnology
Ophthalmic Solutions
Drug Delivery Systems
Biological Availability
Molecular Biology
Pharmacokinetics
Injections

All Science Journal Classification (ASJC) codes

  • Pharmaceutical Science

Cite this

Nanoparticles for drug delivery to the anterior segment of the eye. / Janagam, Dileep R.; Wu, Linfeng; Lowe, Tao.

In: Advanced Drug Delivery Reviews, Vol. 122, 01.12.2017, p. 31-64.

Research output: Contribution to journalReview article

@article{c1cba74ba6ca4436b0a35de80ab618cd,
title = "Nanoparticles for drug delivery to the anterior segment of the eye",
abstract = "Commercially available ocular drug delivery systems are effective but less efficacious to manage diseases/disorders of the anterior segment of the eye. Recent advances in nanotechnology and molecular biology offer a great opportunity for efficacious ocular drug delivery for the treatments of anterior segment diseases/disorders. Nanoparticles have been designed for preparing eye drops or injectable solutions to surmount ocular obstacles faced after administration. Better drug pharmacokinetics, pharmacodynamics, non-specific toxicity, immunogenicity, and biorecognition can be achieved to improve drug efficacy when drugs are loaded in the nanoparticles. Despite the fact that a number of review articles have been published at various points in the past regarding nanoparticles for drug delivery, there is not a review yet focusing on the development of nanoparticles for ocular drug delivery to the anterior segment of the eye. This review fills in the gap and summarizes the development of nanoparticles as drug carriers for improving the penetration and bioavailability of drugs to the anterior segment of the eye.",
author = "Janagam, {Dileep R.} and Linfeng Wu and Tao Lowe",
year = "2017",
month = "12",
day = "1",
doi = "10.1016/j.addr.2017.04.001",
language = "English (US)",
volume = "122",
pages = "31--64",
journal = "Advanced Drug Delivery Reviews",
issn = "0169-409X",
publisher = "Elsevier",

}

TY - JOUR

T1 - Nanoparticles for drug delivery to the anterior segment of the eye

AU - Janagam, Dileep R.

AU - Wu, Linfeng

AU - Lowe, Tao

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Commercially available ocular drug delivery systems are effective but less efficacious to manage diseases/disorders of the anterior segment of the eye. Recent advances in nanotechnology and molecular biology offer a great opportunity for efficacious ocular drug delivery for the treatments of anterior segment diseases/disorders. Nanoparticles have been designed for preparing eye drops or injectable solutions to surmount ocular obstacles faced after administration. Better drug pharmacokinetics, pharmacodynamics, non-specific toxicity, immunogenicity, and biorecognition can be achieved to improve drug efficacy when drugs are loaded in the nanoparticles. Despite the fact that a number of review articles have been published at various points in the past regarding nanoparticles for drug delivery, there is not a review yet focusing on the development of nanoparticles for ocular drug delivery to the anterior segment of the eye. This review fills in the gap and summarizes the development of nanoparticles as drug carriers for improving the penetration and bioavailability of drugs to the anterior segment of the eye.

AB - Commercially available ocular drug delivery systems are effective but less efficacious to manage diseases/disorders of the anterior segment of the eye. Recent advances in nanotechnology and molecular biology offer a great opportunity for efficacious ocular drug delivery for the treatments of anterior segment diseases/disorders. Nanoparticles have been designed for preparing eye drops or injectable solutions to surmount ocular obstacles faced after administration. Better drug pharmacokinetics, pharmacodynamics, non-specific toxicity, immunogenicity, and biorecognition can be achieved to improve drug efficacy when drugs are loaded in the nanoparticles. Despite the fact that a number of review articles have been published at various points in the past regarding nanoparticles for drug delivery, there is not a review yet focusing on the development of nanoparticles for ocular drug delivery to the anterior segment of the eye. This review fills in the gap and summarizes the development of nanoparticles as drug carriers for improving the penetration and bioavailability of drugs to the anterior segment of the eye.

UR - http://www.scopus.com/inward/record.url?scp=85018318087&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018318087&partnerID=8YFLogxK

U2 - 10.1016/j.addr.2017.04.001

DO - 10.1016/j.addr.2017.04.001

M3 - Review article

VL - 122

SP - 31

EP - 64

JO - Advanced Drug Delivery Reviews

JF - Advanced Drug Delivery Reviews

SN - 0169-409X

ER -